Lux Biosciences Names Brett Skolnik Chief Financial Officer

JERSEY CITY, N.J.--(Business Wire)--
Lux Biosciences, Inc., a privately held biotechnology company
specialized in the field of ophthalmic diseases, announced today the
appointment of Brett A. Skolnik as Chief Financial Officer. Mr.
Skolnik was previously a managing director in the Health Care Group at
Piper Jaffray & Company.

"Brett has had an extensive career as a financial executive and
advisor to the biotechnology and pharmaceutical industry and has broad
experience in merger and acquisition transactions, public and private
offerings, and capital and financial management," said Ulrich Grau,
Ph.D., President and Chief Executive Officer of Lux Biosciences. "We
are very pleased to welcome him to the Lux Biosciences management
team. His many years of experience and his network in the financial
community will serve our company well as our first products complete
phase 3 clinical development and our company enters its next stage of
growth."

"I am excited to join Lux Biosciences at this critical time in the
company's development. I believe the company's two late-stage clinical
programs and its diverse pipeline of earlier stage ophthalmic products
hold tremendous clinical and commercial potential," commented Mr.
Skolnik. "I look forward to working with Uli and the Lux management
team as we continue to develop the product portfolio and build value
at the company."

Prior to joining Piper Jaffray & Co., where he was a founding
member of the company's New York banking office, Mr. Skolnik held
positions in the Health Care groups of SG Cowen Securities and Cowen &
Company, and before that in the Mergers and Acquisitions groups of
PaineWebber, Inc. and Kidder Peabody & Co. Mr. Skolnik holds an MBA in
finance from Columbia University and a BS in mechanical engineering
from Lehigh University.

About Lux Biosciences

Lux Biosciences, Inc. is a privately held biotechnology company
focused on ophthalmic diseases. The company has a staged product
portfolio of potentially first-in-class therapies distinguished by
their short-term path to commercialization and potential to generate
high revenue growth. The portfolio includes:

-- Two Phase 3 clinical-stage projects including: i) LX211, the
oral formulation of a next-generation calcineurin inhibitor
(voclosporin) developed as steroid-sparing therapy for the
treatment of non-infectious uveitis, and ii) LX201, a silicone
matrix ocular (episcleral) implant that steadily releases
therapeutic doses of cyclosporine A locally to the eye for the
prevention of rejection in cornea transplant recipients. Both
the LUMINATE pivotal clinical program for LX211 for the
treatment of uveitis, as well as the LUCIDA pivotal clinical
program with LX201 for the prevention of corneal transplant
rejection were initiated in early 2007 and include sites in
North America, Europe and India.

-- LX214, a novel topical eye drop formulation currently in
IND-enabling studies with a target date for entry into the
clinic in 2008. LX214 is based on Lux' proprietary
next-generation calcineurin inhibitor and is targeted towards
other chronic inflammatory diseases of the eye, most notably
dry eye syndrome, blepharitis and atopic keratoconjunctivitis.

-- Several earlier stage projects based on proprietary
product-enabling bio-erodible polymer technologies that
facilitate targeted and sustained delivery of molecules to the
eye.

For more information on Lux Biosciences, please visit the
company's website at http://www.luxbio.com.

Lux Biosciences, Inc.
Ulrich Grau, Ph.D., +1-201-946-0221
Ulrich.grau@luxbio.com
or
Kureczka/Martin Associates
Joan Kureczka, +1-415-821-2413 (media)
Jkureczka@comcast.net

Copyright Business Wire 2008